



## Curriculum Vitae

### Personal information David Olsen

#### Work experience

---

1. Employer: Statens Legemiddelverk (Norwegian Medicines Agency, as of 1. Jan 2024 Norwegian Medicinal Product Agency)
  - Start date: 102015
  - End date:
  - Position: Senior advisor, MD
  - Activities: Drug safety assessment, pharmacovigilance activities, PRAC member, clinical expert
  - Country: Norway
2. Employer: Sanofi Pasteur MSD
  - Start date: 042013
  - End date: 102015
  - Position: Deputy director Nordic Medical affairs and director Nordic medical affairs
  - Activities: Vaccines, drug safety
  - Country: Norway
3. Employer: Merck Serono
  - Start date: 092010
  - End date: 042013
  - Position: Medical director
  - Activities: Various products
  - Country: Norway
4. Employer: Gilead Sciences
  - Start date: 082009
  - End date: 092010
  - Position: Nordic medical manager
  - Activities: Various products
  - Country: Sweden
5. Employer: Merck serono
  - Start date: 082006
  - End date: 082009
  - Position: Medical manager and medical director
  - Activities: Various products
  - Country: Denmark
6. Employer: Boehringer Ingelheim
  - Start date: 112004
  - End date: 082006
  - Position: Medical advisor
  - Activities: Various products
  - Country: Denmark
7. Employer: Rigshospitalet and Copenhagen Muscle Research center
  - Start date: 012000
  - End date: 112004
  - Position: Researcher
  - Activities: Physician, Department of Neurology, Rigshospitalet, University of Copenhagen and Basic muscle physiology and pathology research at CMRC
  - Country: Denmark
8. Employer: University Hospital Copenhagen (various departments)
  - Start date: 011996
  - End date: 012000
  - Position: Physician
  - Activities: Internship (physician) at various departments. Research assistant at the MS Research unit, Glostrup Hospital, University of Copenhagen
  - Country: Denmark

#### Education and training

---

1. Subject: University of Copenhagen
  - Start date: 021989
  - End date: 011996
  - Qualification: Medical Doctor (Cand Med)
  - Organisation: Medical Doctor Authorized physician
  - Country: Denmark

#### Additional information

---

##### Publications

Olsen DB, Abraham JH. Neuropsykiatriske forstyrrelser ved insulinom. Ugeskr Laeger 1999;161:1420\_21. Olsen DB, Langkilde AR, Schmalbruch H, Vissing J. Diagnostic challenges in combined multiple sclerosis and centronuclear myopathy. Eur J Neurol 2000;7(5):567\_571. Olsen DB, Langkilde AR, Rostrup E, Ørngreen MC, Vissing J. Muscle structural changes in mitochondrial myopathy relate to genotype. J Neurol 2003;250:1328\_1334. Olsen DB, Ørngreen MC, Vissing J. Aerobic training improves exercise performance in facioscapulohumeral muscular dystrophy.

Neurology 2005;64:1064\_1066. Olsen DB, Sacchetti M, Dela F, Ploug T, Saltin B. Glucose clearance is higher in arm than leg muscle in type 2 diabetes. *J Physiol* 2005;565:555\_562. Olsen DB, Gideon P, Jeppesen TD, Vissing J. Leg muscle involvement in fascioscapulohumeral muscular dystrophy assessed by MRI. *J Neurol*. 2006;253:1437\_41. Olsen DB, Scheede\_Bergdahl C, Reving D, Boushel R, Dela F. The effect of rowing on endothelial function and insulin action in healthy controls and in patients with type 2 diabetes. *Scand J Med Sci Sports*. 2010 Feb 4. [Epub ahead of print] Olsen DB. Vaksinasjon mot helvetesild. *Tidsskrift for den Norske Legeforening*. 2015;135:834 Olsen DB, Baftiu A. Valproat er kontraindisert ved graviditet. *Tidsskr Nor Legeforen*. 2019 Munch\_Andersen T, Olsen DB, Sondergaard H, Daugaard JR, Bysted A, Christensen DL, Saltin B, Helge JW. Metabolic profile in two physically active inuit groups consuming either a western or a traditional diet. *Int J Circumpolar Health* 2012;71:17342 Sacchetti M, Olsen DB, Saltin B, Van Hall G. Heterogeneity in limb fatty acid kinetics in type 2 diabetes. *Diabetologia* 2005;48:938\_945. González-Alonso J, Olsen DB, Saltin B. Erythrocyte and the regulation of human skeletal muscle blood flow and oxygen delivery. Role of circulating ATP. *Circ Res* 2002;91(11):1046\_55 Ørngreen MC, Olsen DB, Vissing J. Exercise tolerance in carnitine palmitoyltransferase II deficiency with i.v. and oral glucose. *Neurology* 2002;59(7):1046\_51. Jeppesen TD, Olsen DB, Vissing J. Cycle ergometry is not a sensitive diagnostic test for mitochondrial myopathy. *J Neurol* 2003;250:293\_299. Ørngreen MC, Olsen DB, Vissing J. Aerobic training in patients with myotonic dystrophy type I. *Ann Neurol* 2005;57:754\_757. Jensen TD, Schwartz M, Olsen DB, Vissing J. Oxidative capacity correlates with muscle mutation load in mitochondrial myopathy. *Ann Neurol* 2003;54:86\_92. Sacchetti M, Saltin B, Olsen DB, van Hall G. High triacylglycerol turnover rate in human skeletal muscle. *J Physiol* 2004;15:883\_891. Jeppesen TD, Schwartz M, Olsen DB, Wibrand F, Krag T, Duno M, Hauerslev S, Vissing J. Aerobic training is safe and improves exercise capacity in patients with mitochondrial myopathy. *Brain*. 2006;129:3402\_12 Sonne MP, Scheede\_Bergdal C, Olsen DB, Højbjerg L, Nielsen NB, Stallknecht B, Helge JW, Dela F. Effects of physical training on endothelial function and limb blood flow in type 2 diabetes. *Appl Physiol Nutr Metab* 2007;32:936\_941. Holmøy T, Fevang B, Olsen DB, Spigset O, Bø L. Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis. *BMC Res Notes* 2019;12:497 Ørngreen MC, Gideon P, Pedersen HB, Olsen DB, Vissing J. Juvenil asymmetrisk segmental spinal muskel atrofi. *Ugeskr Læger* 2002;164(35):4073\_4075. Sonne MP, Scheede\_Bergdahl C, Olsen DB, Højbjerg L, Alibegovic A, Nielsen NB, Stallknecht B, Helge JW, Vaag A, Dela F. Effects of physical training on endothelial function and limb blood flow in type 2 diabetes. *APNM* 2007 (in press) Wibrand F, Jeppesen TD, Frederiksen AL, Olsen DB, Duno M, Schwartz M, Vissing J. Limited diagnostic value of enzyme analysis in patients with mitochondrial tRNA mutations. *Muscle Nerve*. 2009 Nov 25. [Epub ahead of print] Caray AL, Bruce CR, Sacchetti M, Anderson MJ, Olsen DB, Saltin B, Hawley JA, Febbraio MA. Interleukin\_6 and tumor necrosis factor\_alpha are not increased in patients with type 2 diabetes: evidence that plasma interleukin\_6 related to fat mass and not insulin responsiveness. *Diabetologia* 2004;47:1029\_1037. Jeppesen TD, Schwartz M, Frederiksen AL, Wibrand F, Olsen DB, Vissing J. Muscle phenotype and mutation load in 51 persons with the 3243A>G mitochondrial DNA mutation. *Arch Neurol* 2006;63:1701\_6 Klarskov P, Bang LE, Schultz\_Larsen P, Petersen HG, Olsen DB, Berg RMG, Abrahamsen H, Wiinberg N. Intensive versus conventional blood pressure monitoring in a general practice population. The blood pressure reduction in Danish general practice trial: a randomized controlled parallel group trial. *Fam Pract* 2018 Jan 17 Sørensen TL, Trebst C, Kivisäkk P, Klaege KL, Majmudar A, Ravid R, Lasmann H, Olsen DB, Strieter RM, Ransohoff RM, Sellebjerg F. Multiple sclerosis: a study of CXCL10 and CXCR3 colocalisation in the inflamed central nervous system. *J Neuroimmunol* 2002;127:59\_68. Plueschke K, Flynn R, Hedenmalm K, Deli AC, Maciá-Martinez MA, García-Poza P, Olsen D, Nguyen P, Quinten C. Prescribing patterns of codeine and alternative medicines in children in Europe. *Drug Safe* 2022 Oct 45(10):1069\_81.

[Projects](#)

[Memberships](#)

[Other Relevant Information](#)